Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Torcytech-S is a fixed-dose combination oral medication developed and marketed by Cytech Pharma in India. It contains 10 mg of torasemide and 50 mg of spironolactone. Torasemide is a loop diuretic that inhibits the Na+-K+-2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to significant excretion of water and electrolytes. Spironolactone is a potassium-sparing diuretic that acts as a competitive antagonist of the mineralocorticoid receptor (aldosterone receptor), primarily in the distal renal tubules. By combining these two agents, Torcytech-S effectively manages edema and fluid retention associated with congestive heart failure, liver cirrhosis with ascites, and nephrotic syndrome, while helping to maintain potassium balance. It is particularly indicated when a potassium-sparing adjunct is necessary to prevent hypokalemia induced by loop diuretics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Torcytech-S.